logo

BCRX

BioCryst Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)

BCRX fundamentals

BioCryst Pharmaceuticals (BCRX) expects to report earnings on Feb 26, 2026, with estimated revenue of 151.32M (YoY +15.05%), and EPS at 0.0483 (YoY +137.15%).
Revenue estimate / YoY
151.32M
+15.05%
EPS estimate / YoY
0.0483
+137.15%
Report date
Feb 26, 2026
Earnings Call
8:30 AM on Feb 26, 2026
Meeting link.
EPS
Revenue

Revenue & Expenses

BCRX has released its 2025 Q3 earnings report, with revenue of 159.40M, reflecting a YoY change of 36.14%, and net profit of 12.90M, showing a YoY change of 191.92%. The Sankey diagram below clearly presents BCRX's revenue sources and cost distribution.

Key Indicators

BioCryst Pharmaceuticals (BCRX) key financial stats and ratios, covering profitability, financial health, and leverage.
BioCryst Pharmaceuticals (BCRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
BioCryst Pharmaceuticals (BCRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
BioCryst Pharmaceuticals (BCRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does BioCryst Pharmaceuticals (BCRX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track BioCryst Pharmaceuticals (BCRX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield